24649-69-2Relevant articles and documents
Preparation of a fludarabine intermediate via selective alkylation of 2-fluoroadenine
Schulmeier, Brian,Cantrell, William,Bauta, William
, p. 735 - 745 (2006)
The reaction between 2-fluoroadenine ( 3 ) and 1,3,5-tri- O -benzyl-1- α -d-chloroarabinofuranose ( 4 ) with potassium t- amylate was evaluated in various solvents to afford 9- β -d-(2,3,5-tri- O -benzyl- arabinofuranosyl)-2-fluoroadenine ( 5 ) and the co
6-azido-2-fluoropurine, useful in the synthesis of nucleosides
-
, (2008/06/13)
This invention pertains to novel methods of synthesizing fludarabine, fludarabine phosphate and related nucleoside pharmacologic agents utilizing 6-azido-2-fluoropurine as a novel intermediate. In particular this invention pertains to a synthesis of fludarabine where the relatively low yield fluorination step is done before the costly coupling step.
Anticancer and antiviral activity of 9-β-D-arabinofuranosyl-2-fluoroadenine
-
, (2008/06/13)
A method of utilizing 9-β-D-arabinofuranosyl-2-fluoroadenine, known as 2-F-AraA (NSC 118218), in the treatment of murine leukemia and as an antiviral agent for DNA viruses, such as DNA viruses Herpes Simplex Virus Type I and Vaccinia virus grown in H.Ep-2 cells in culture. An operable dosage for utilization of 2-F-AraA is a treatment span of 1-10 days with the dosage 2-8 times per day at 8-400 mg/kg/dose. It has been further found that a single dosage on days 1, 5, and 9 based on a 10-day treatment schedule gave satisfactory results.